Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News

03:36 EDT 20th September 2017 | BioPortfolio

Showing News Articles 1–25 of 1,100,000+

Wednesday 20th September 2017

D3 Agonist Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, D3 AgonistMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across D3 Agonist. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics assessment of D3 Agonist by development stage, therapy ...

CyclinDependent Kinase Inhibitor Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, CyclinDependent Kinase InhibitorMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across CyclinDependent Kinase Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics assessment ...

Prexton Therapeutics SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 22082017] Prices from USD $250

SummaryPrexton Therapeutics SA Prexton is a drug development company that develops drugs for Parkinson's disease and other brain disorders. The company specializes in the designing of mGluR4 PAM compounds for the treatment for Parkinson's disease. It also develops positive allosteric modulators, or PAMs to increase mGluR4 activity. The company's product pipeline includes new chemical entities, whi...

Appili Therapeutics Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 22082017] Prices from USD $250

SummaryAppili Therapeutics Appili Therapeutics is a developer of therapeutic products that provides treatment of infectious diseases. The company develops novel agents for antivirals, antifungals, antiparasitics and antimicrobials to treat infections caused by multidrug resistant pathogens. It is developing novel strategies to bring novel classes of antibiotics and antiinfectives, for the improved...

Novartis's Rydapt wins EU approval for AML, other diseases

ZURICH (Reuters) - Swiss drugmaker Novartis on Wednesday said it had won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML) and other rare diseases, adding to U.S. approvals it secured in April.

Global Collaborative RD Partnering Terms and Agreements in Pharma, Biotech Diagnostics 20122017 [Report Updated: 01092017] Prices from USD $2995

The Global Collaborative RD Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 20122017 report provides comprehensive understanding and unprecedented access to the collaborative RD deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest collaborative RD deals announced in the pharmaceutical, biotechnology and diagno...

Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences

Synpromics Ltd, the leader in gene control, today announces a new research partnership with Solid Biosciences, LLC. Under the terms of the agreement, Synpromics will provide Solid Biosciences access to a set of key muscle-selective promoter candidates to be used in the development of new treatment options for Du

Numab Innovation AG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24082017] Prices from USD $250

SummaryNumab Innovation AG Numab designs and develops novel therapeutics for the treatment of severe diseases. The company's lead program ND007, a bispecific antibody fragment which is being evaluated for the treatment of autoimmune diseases. Numab's other pipeline drug candidates include ND009, ND016, ND017 and other multiple programs are being development to treat inflammatory bowel disease, aut...

Poxel Announces PXL770 Advances into a Phase 1b Multiple Ascending Dose Trial

PXL770 is a direct AMPK activator; a central regulator of multiple metabolic pathways that provides the opportunity to treat a wide range of metabolic diseases POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including

PureTech Health Notes U.S. Patent Issuance Broadly Covering Methods of Assessing Mental and Physical Condition from Human Speech

PureTech Health plc (“PureTech Health” or the “Company”, LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,763,617 for its Sonde vocal biomarkers program. The patent broadly covers methods of assessing a mental or physical con...

GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations

Trelegy Ellipta met study primary endpoint demonstrating reduction in exacerbations compared with the dual therapies Anoro Ellipta and Relvar/Breo Ellipta in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta, the ...

ME Association Summary Report of the 4th Annual CMRC Research Conference in Bristol | 20 September 2017

  By Dr Charles Shepherd, Hon. Medical Adviser to the ME Association Introduction This is a summary report of what I felt were the highlights and main points to emerge...

Global MS Resin SMMA Market Data Survey Report 2025 [Report Updated: 09082017] Prices from USD $1500

SummaryMS Resin, also known as SMMA, is a transparent copolymer primarily composed of methyl methacrylate MMA and styrene monomer SM. It has excellent transparency, optical property, good weatherresistivity, easy to process, low hygroscopicity, low residual stress for molded products, and therefore economical for many applications.The global MS Resin SMMA market will reach xxx Million USD in 2017 ...

Global Silicon Nitride Powder Market Research Report 20112023 [Report Updated: 01092017] Prices from USD $2280

SummarySilicon nitride Si3N4 is one of the purely covalent nitrides. Like all nitrides, it is characterized by a high degree of thermal stability and exceptional chemical stability. Its other properties make it the top representative of the nitride ceramics.The global Silicon Nitride Powder market will reach Volume Million USD in 2017 with CAGR xx% 20182023. The objective of report is to define, s...

Global Moisture Resistant Honeycomb Core Market Research Report Forecast 20172022 [Report Updated: 25062017] Prices from USD $2800

Delivery of the Report will take 4872 hours once order is placed.The Global Moisture Resistant Honeycomb Core Market Research Report Forecast 20172022 is a valuable source of insightful data for business strategists. It provides the Moisture Resistant Honeycomb Core industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research...

Delta Antagonist Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, Delta AntagonistMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Delta Antagonist. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics assessment of Delta Antagonist by developme...

DelMar Pharma OK'd to Start Trial of Lead Drug in Ovarian Cancer Patients

DelMar Pharma was approved to start a Phase I trial of its lead molecule, VAL-083, in patients with ovarian cancer. The US trial is the second indication for VAl-083, which is already in US and China trials for refractory brain cancer. Several years ago, when DelMar started looking for a supplier of VAL-083, it discovered that Guangxi Wuzhou Pharma offered the drug in China for leukemia and lung c...

Global Cookies Cream Proteins Market Research Report Forecast 20172022 [Report Updated: 17062017] Prices from USD $2800

Delivery of the Report will take 4872 hours once order is placed.The Global Cookies Cream Proteins Market Research Report Forecast 20172022 is a valuable source of insightful data for business strategists. It provides the Cookies Cream Proteins industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research analysts provide an...

InnoPharma Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23082017] Prices from USD $250

SummaryInnoPharma Inc InnoPharma, a subsidiary of Pfizer Inc is a healthcare products provider that develops generic and pharmaceutical products. The company develops formulations, which include solutions, suspensions, lyophilized, emulsions, liposomes, lipid complexes, polypeptides and carbohydrates, and novel formulations of existing drugs. Its technology platform include lyophilization, microni...

The Scripps Research Institute Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23082017] Prices from USD $250

SummaryThe Scripps Research Institute TSRI is a research and educational organization that conducts research in the areas of neurosciences, cardiovascular diseases, immunology, autoimmune diseases, chemistry, molecular and cellular biology, virology and synthetic vaccine development. The institute offers technology and scientific services such as antibody development and production, cell based scr...

Global Pancreatic Cancer Partnering 2010 to 2017 [Report Updated: 01092017] Prices from USD $1495

The Global Pancreatic Cancer Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. Trends in partnering deals Top deals by value Deals listed by company AZ, industry sector, stage of development, technology typeThe report provides understanding and access to the partnering dea...

Stemline Therapeutics Inc STML Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 22082017] Prices from USD $250

SummaryStemline Therapeutics Inc Stemline is a clinical stage biopharmaceutical company that develops therapeutics to treat cancer stem cells and tumor bulk. The company has developed discovery platform StemScreen to identify novel compounds that target and kill cancer stem cells. Its products pipeline comprise SL401, SL701, SL801, SL501 and SL101. Stemline's SL401 is a targeted therapy directed t...

Global Low Trauma/Skin Friendly Adhesives Market Research Report 20112023 [Report Updated: 30082017] Prices from USD $2280

SummaryLow trauma adhesives are skinfriendly adhesives for bandages, dressings and surgical tapes. The goal is not only to alleviate pain when removing skin adhesives, but also to avoid exacerbating existing wounds and ulcers or creating new ones."The global Low Trauma/Skin Friendly Adhesives market will reach Volume Million USD in 2017 with CAGR xx% 20182023. The objective of report is to define,...

Finox AG Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 22082017] Prices from USD $250

SummaryFinox AG Finox, a subsidiary of Richter Gedeon Nyrt is a drug development and manufacturing company that offers fertility treatment products. The company develops drugs in the field of fertility therapies. Its portfolio spans biosimilars and patient friendly delivery devices. Finox offers bemfola, a recombinanthuman folliclestimulating hormone used to stimulate the ovaries in the context of...

Tuesday 19th September 2017

Thomson Reuters Announces Top U.S. Hospitals for Heart Care

ANN ARBOR, Mich., Nov. 14, 2011 /PRNewswire/ -- Thomson Reuters today released its annual study identifying the top U.S. hospitals for inpatient cardiovascular services. (Logo:  http://photos.prnewswire.com/prnh/20090507/NY12658LOGO ) The study, in its thirteenth year, singled out 50 hospitals that achieved superior clinical outcomes. "This year's 50 Top Cardiovascular Hospitals have continue...


Quick Search
Advertisement
 

BioPortfolio's biotechnology, pharmaceutical, healthcare and medical device information service collates press releases, news articles and blogs from over 275 sources.